-
公开(公告)号：US06696494B2
公开(公告)日：2004-02-24
申请号：US10007235
申请日：2001-10-22
申请人： Yat Sun Or , Guoqiang Wang , John Rougas , Jude Elizabeth Mathews , Kate Ryan Muldoon , Vincent Alfred Boyd , Jens Werner Eckstein , Steven Wayne Riesinger
发明人： Yat Sun Or , Guoqiang Wang , John Rougas , Jude Elizabeth Mathews , Kate Ryan Muldoon , Vincent Alfred Boyd , Jens Werner Eckstein , Steven Wayne Riesinger
IPC分类号： A61K31165
CPC分类号： C07D295/192 , C07C235/42 , C07C235/52 , C07C235/74 , C07C235/76 , C07C235/84 , C07C237/12 , C07C237/36 , C07C271/22 , C07C275/24 , C07C275/28 , C07C275/30 , C07C311/06 , C07C311/19 , C07C311/51 , C07C323/60 , C07C333/04 , C07C2601/14 , C07D213/65 , C07D213/71 , C07D215/36 , C07D261/08 , C07D271/12 , C07D279/30 , C07D295/215 , C07D307/20 , C07D311/24 , C07D333/34
摘要： Acylated &agr;-hydroxyarylbutanamines and related sulfonamides, ureas and carbamates that inhibit aspartyl protease are disclosed, as are methods of treating diseases, particularly HIV, using these compounds. The compounds have the formula: A representative example is:
摘要翻译： 公开了抑制天冬氨酰蛋白酶的酰化α-羟基芳基丁胺和相关磺酰胺，脲和氨基甲酸酯，以及使用这些化合物治疗疾病，特别是HIV的方法。 化合物具有以下化学式：代表性的实例是：
-
公开(公告)号：US06979671B2
公开(公告)日：2005-12-27
申请号：US10349877
申请日：2003-01-23
摘要： The present invention relates to a cyclosporin analog of the following formula (I) or its pro-drug or pharmaceutically acceptable salt: In formula I, the formula for residue A is: where X and Y are defined according to the claimed invention the present invention also relates to pharmaceutical compositions comprising pro-drugs or pharmaceutically acceptable salts of the compounds of the present invention and the use thereof for treating an inflammatory or immune disorder in a subject need of such treatment.
摘要翻译： 本发明涉及下式（I）的环孢菌素类似物或其前药或药学上可接受的盐：在式I中，残基A的化学式为：其中X和Y根据要求保护的发明定义，本发明 还涉及包含本发明化合物的前药或药学上可接受的盐的药物组合物及其用于治疗受试者需要这种治疗的炎症或免疫疾病的用途。
-
公开(公告)号：US07012064B2
公开(公告)日：2006-03-14
申请号：US10349890
申请日：2003-01-23
摘要： The present invention relates to methods of treating or preventing an inflammatory or immune disorder in a subject while eliminating or reducing the toxicity associated with the administration of cyclosporin A, comprising systemically administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, in combination with a pharmaceutically acceptable carrier or excipient: in Formula (I), the formula for residue A is:
摘要翻译： 本发明涉及在消除或降低与环孢菌素A的给药相关的毒性的同时治疗或预防受试者的炎性或免疫病症的方法，包括向所述受试者全身施用包含治疗有效量的至少一种 式（I）化合物或其药学上可接受的盐，酯或前药与药学上可接受的载体或赋形剂组合：在式（I）中，残基A的式为：
-
-
搜索结果
3 条记录 (耗时 0.042 秒)
